tradingkey.logo
搜尋

Beta Bionics Inc

BBNX
添加自選
13.300USD
+0.470+3.66%
收盤 07-31 16:00美東報價延遲15分鐘
598.26M總市值
虧損本益比TTM

關於 Beta Bionics Inc 公司

Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.

Beta Bionics Inc簡介

公司代碼BBNX
公司名稱Beta Bionics Inc
上市日期Jan 30, 2025
CEOSaint (Sean)
員工數量291
證券類型Ordinary Share
年結日Jan 30
公司地址11 Hughes
城市IRVINE
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編92618
電話19494277785
網址https://www.betabionics.com
公司代碼BBNX
上市日期Jan 30, 2025
CEOSaint (Sean)

Beta Bionics Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Dr. Steven Russell, M.D., Ph.D.
Dr. Steven Russell, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
173.85K
-2.43%
Mr. Mark Hopman
Mr. Mark Hopman
Chief Commercial Officer
Chief Commercial Officer
94.35K
-7.27%
Mr. Gerard J. Michel
Mr. Gerard J. Michel
Independent Director
Independent Director
29.51K
+57.49%
Mr. Sean D. Carney
Mr. Sean D. Carney
Independent Director
Independent Director
28.21K
+60.13%
Dr. Maria Palasis, Ph.D.
Dr. Maria Palasis, Ph.D.
Independent Director
Independent Director
25.40K
+66.79%
Mr. Adam Lezack
Mr. Adam Lezack
Independent Chairman of the Board
Independent Chairman of the Board
23.40K
+63.96%
Ms. Christy Jones
Ms. Christy Jones
Independent Director
Independent Director
22.00K
-19.17%
Mr. Sean Saint
Mr. Sean Saint
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
5.67K
-297.67%
Mr. Stephen Feider
Mr. Stephen Feider
Chief Financial Officer
Chief Financial Officer
3.18K
-210.20%
Mr. Michael (Mike) Mensinger
Mr. Michael (Mike) Mensinger
Chief Product Officer
Chief Product Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Steven Russell, M.D., Ph.D.
Dr. Steven Russell, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
173.85K
-2.43%
Mr. Mark Hopman
Mr. Mark Hopman
Chief Commercial Officer
Chief Commercial Officer
94.35K
-7.27%
Mr. Gerard J. Michel
Mr. Gerard J. Michel
Independent Director
Independent Director
29.51K
+57.49%
Mr. Sean D. Carney
Mr. Sean D. Carney
Independent Director
Independent Director
28.21K
+60.13%
Dr. Maria Palasis, Ph.D.
Dr. Maria Palasis, Ph.D.
Independent Director
Independent Director
25.40K
+66.79%
Mr. Adam Lezack
Mr. Adam Lezack
Independent Chairman of the Board
Independent Chairman of the Board
23.40K
+63.96%

常見問題

Beta Bionics Inc的前五大股東是誰?

Beta Bionics Inc的前五大股東如下:Dr. Steven Russell, M.D., Ph.D.

有多少機構持有Beta Bionics Inc(BBNX)的股份?

截至2026Q1,共有264家機構持有Beta Bionics Inc的股份,合計持有的股份價值約為49.25M,占公司總股份的110.51% 。與2025Q4相比,機構持股有所增加,增幅為-2186348.00。

哪個業務部門對Beta Bionics Inc的收入貢獻最大?

在2026Q1,DME channel - iLet業務部門對Beta Bionics Inc的收入貢獻最大,創收52.05M,占總收入的51.92% 。
tradingkey.logo
風險提示:我們的網站和行動應用程式僅提供關於某些投資產品的一般資訊。Finsights 不提供財務建議或對任何投資產品的推薦,且提供此類資訊不應被解釋為 Finsights 提供財務建議或推薦。
投資產品存在重大投資風險,包括可能損失投資的本金,且可能並不適合所有人。投資產品的過去表現並不代表其未來表現。
Finsights 可能允許第三方廣告商或關聯公司在我們的網站或行動應用程式的任何部分放置或投放廣告,並可能根據您與廣告的互動情況獲得報酬。
© 版權所有: FINSIGHTS MEDIA PTE. LTD. 版權所有